Clinical Evaluation of Nisha Katakadi Kashaya and Yashada Bhasma in the Management of Type II Diabetes Mellitus(Madhumeha). - Not Applicable

Central Council for Research in Ayurvedic Sciences CCRAS0 个研究点目标入组 240 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients who are diagnosed to be Type II Diabetics by either HbA1c >6.5%. or BS-F >126 mg% of BS-PP >200 mg% / Diabetics who are on lifestyle modification & /or on Tab.Metformin upto 2gm/ day.
•2. Willing to participate in clinical trial.

•1. Patients already diagnosed to be suffering from the complications of Diabetes Mellitus viz., diabetic neuropathy, diabetic nephropathy,
•diabetic retinopathy, etc.
•2. Patients suffering from Type-I / brittle diabetes mellitus.
•3. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•4. Patient with poorly controlled Hypertension ( >140 / 90 mm Hg).
•5. Patient with poorly controlled Gycemic status(HbA1c >8 %).
•6. Symptomatic patient with clinical evidence of Heart failure.
•7. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl),uncontrolled
•Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
•8. Pregnant / Lactating women.
•9. Patient on steroids, oral contraceptive pills or estrogen replacement therapy.
•10. Alcoholics and/or drug abusers.
•11. Patients with evidence of malignancy.
•12. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.)
•13. H/o hypersensitivity to any of the trial drugs or their ingredients.
•14. Patients who have completed participation in any other clinical trial during the past six (06) months.
•15. Any other condition which the Investigator thinks may jeopardize the study.

发起方

Central Council for Research in Ayurvedic Sciences CCRAS